[1] 邹杰民. 基于乳腺癌基因组数据的分析与可视化平台实现[D]. 长沙:湖南大学, 2017. [2] Mahrooghy M, Ahmed A, Daye D, et al. Pharmacokinetic tumor heterogeneity as a prognostic biomarker for classifying breast cancer recurrence risk[J]. IEEE Transactions on Biomedical Engineering, 2015, 62(6):1585-1587. [3] Xu Yanxun, Zhang Jie, Yuan Yuan, et al. A bayesian graphical model for integrative analysis of TCGA data[J]. International Workshop on Genomic Signal Processing and Statistics, 2012(12):2-4. [4] 姜鑫钊, 张明龙, 杜媛媛, 等. APOBEC3基因拷贝数变异与乳腺癌易感性的关联[J]. 基因组学与应用生物学, 2019(3):1315-1321. Jiang Xinzhao, Zhang Minglong, Du Yuanyuan, et al. Correlation between copy number variation of APOBEC3 gene and breast cancer susceptibility[J]. Genomics and Applied Biology, 2019(3):1315-1321. [5] Freeman S S, Allen S W, Ganti R, et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors[J]. Cancer, 2008, 113(6):1453-1461. [6] Sheng Chen, Feifei Gu, Kang Li, et al. A hybrid of B and T lymphoblastic cell line could potentially substitute dendritic cells to efficiently expand out Her-2/neu-specific cytotoxic T lymphocytes from advanced breast cancer patients in vitro[J]. Journal of Hematology & Oncology, 2017, 10(1):63. [7] 李莹莹, 董丽儒, 李宇阳, 等. PD-1/PD-L1在非特殊型浸润性乳腺癌中的表达及意义[J]. 广东医学, 2018(11):1690-1693. Li Yingying, Dong Liru, Li Yuyang, et al. The expression and significance of PD-1/PD-L1 in nonspecific invasive breast cancer[J]. Guangdong Medical Journal, 2018(11):1690-1693. [8] 董赟. 单双侧原发性乳腺癌HER-2基因扩增差异及与临床预后的关系分析[D]. 南昌:南昌大学, 2016. [9] 史源, 胡建民. 乳腺癌患者血清BRMS1mRNA的表达及意义分析[J]. 临床研究, 2019, 27(11):108-109. Shi Yuan, Hu Jianmin. Expression and significance of BRMS1mRNA in breast cancer patients[J]. Clinical Research, 2019, 27(11):108-109. [10] Luoh S W, Wagoner W, Wang Xiaoyan, et al. GRB7 dependent proliferation of basal-like, HER-2 positive human breast cancer cell lines is mediated in part by HER-1 signaling[J]. Mol Carcinog, 2019, 58(5):1-7. [11] Dong Ying, Zhang Ting, Li Xining, et al. Comprehensive analysis of coexpressed long noncoding RNAs and genes in breast cancer[J]. J Obstet Gynaecol Res, 2018, 45(2):428-437. [12] Mohammed A, Zhang Caixin, Zhang Shuwen, et al. Inhibition of cell proliferation and migration in non-small cell lung cancer cells through the suppression of LYPLA1[J]. Oncology Reports, 2019, 41(2):973-975. [13] Bhandari A, Shen Yanyan, Sindan N, et al. MAL2 promotes proliferation, migration, and invasion through regulating epithelial-mesenchymal transition in breast cancer cell lines[J]. Biochem Biophys Res Commun, 2018, 504(2):434-439. [14] Lacle M M, Moelans C B, Kornegoor R, et al. Chromosome 17 copy number changes in male breast cancer[J]. Cell Oncol, 2015, 38(3):1-9. [15] Leachman Na T, Brellier F, Ferralli J, et al. ATAD2B is a phylogenetically conserved nuclear protein expressed during neuronal differentiation and tumorigenesis[J]. Develop Growth Differ, 2010, 52(9):747-755. [16] Sio Y Y, Anantharaman R, Lee S Q E, et al. The asthma-associated PER1-like domain-containing protein 1(PERLD1) haplotype influences soluble glycosylphosphatidylinositol anchor protein (sGPI-AP) levels in serum and immune cell proliferation[J]. Scientific Reports, 2020, 10(1):1-11. [17] Pan Xiaoyong, Hu Xiaohua, Zhang Yuhang, et al. Identification of the copy number variant biomarkers for breast cancer subtypes[J]. Molecular Genetics and Genomics, 2019, 294:95-110. [18] Felicio1 P S, Bidinotto L T, Melendez M E, et al. Genetic alterations detected by comparative genomic hybridization in BRCAX breast and ovarian cancers of Brazilian population[J]. Oncotarget, 2018, 9:27525-27534. [19] Qi Feng, Qin Wenxing,Zang Yuansheng, et al.Molecular mechanism of triple-negative breast cancer-associated brca1 and the identification of signaling pathways[J]. Oncology Letters, 2019, 17(3):2905-2914. [20] Cámara Y, Asin-Cayuela J, Park C B, et al. MTERF4 regulates translation by targeting the methyltransferase NSUN4 to the mammalian mitochondrial ribosome[J]. Cell Metabolism, 2011, 13(5):527-539. [21] Wang Ke, Li Ling, Fu Liang, et al. Integrated bioinformatics analysis the function of RNA binding proteins (RBPs) and their prognostic value in breast cancer[J]. Original Research Article, 2019, 10:1-11. [22] Gao H, Duan Y, Fu X, et al. Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules[J]. PLoS ONE, 2018, 13(12):1-18. [23] Gao Hong, Duan Yuhong, Fu Xiaoxu, et al. Comparison of efficacy of SHENQI compound and rosiglitazone in the treatment of diabetic vasculopathy analyzing multi-factor mediated disease-causing modules[J]. PLoS One, 2018, 13(12):1-18. |